Enanta Pharmaceuticals | ENTA - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 33.67B 140M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Anika Therapeutics USD 99.19M 5.63M 2026-06
Arrowhead Research USD 1.67B 168.34M 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
BioCryst Pharmaceuticals USD 484.68M 111.06M 2026-06
Biogen USD 7.31B 1.88B 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 12.53B 6.11B 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
Halozyme Therapeutics USD 933.02M 70.01M 2026-06
Heron Therapeutics USD 229.84M 861K 2026-06
Immunic USD 188.76M 165.89M 2026-03
Incyte USD 6.03B 542.31M 2026-06
Insmed USD 1.63B 20.75M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
J&J USD 59.77B 601M 2026-06
Karyopharm Therapeutics USD 126.33M 23.19M 2026-03
Ligand Pharmaceuticals USD 1.46B 591.7M 2026-06
Merck USD 36.68B 1.66B 2026-06
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06
Novavax USD 771.1M 79.72M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06